Furthermore, in CRC, hypermethylation of the RASSF2 promoter appears to be more frequently associated with the presence of a KRAS mutation [19,28,29,32], although Hesson et al. instead describe an inverse relationship between the frequency of RASSF2 hypermethylation and the frequency of KRAS mutation [26]. The gene discussed is KRAS; the disease is colorectal carcinoma.